1521 Stock Overview
Frontage Holdings Corporation, a contract research organization, provides laboratory and related services to pharmaceutical, biotechnology, and agrochemical companies.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Frontage Holdings Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.35 |
| 52 Week High | HK$2.58 |
| 52 Week Low | HK$1.21 |
| Beta | 0.81 |
| 1 Month Change | -3.57% |
| 3 Month Change | -12.90% |
| 1 Year Change | -40.53% |
| 3 Year Change | -72.56% |
| 5 Year Change | n/a |
| Change since IPO | -68.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1521 | HK Life Sciences | HK Market | |
|---|---|---|---|
| 7D | 5.5% | 4.2% | 2.2% |
| 1Y | -40.5% | -64.9% | -7.9% |
Return vs Industry: 1521 exceeded the Hong Kong Life Sciences industry which returned -63% over the past year.
Return vs Market: 1521 underperformed the Hong Kong Market which returned -8.1% over the past year.
Price Volatility
| 1521 volatility | |
|---|---|
| 1521 Average Weekly Movement | 8.1% |
| Life Sciences Industry Average Movement | 10.8% |
| Market Average Movement | 7.5% |
| 10% most volatile stocks in HK Market | 14.9% |
| 10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 1521's share price has been volatile over the past 3 months.
Volatility Over Time: 1521's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 1,759 | Abdul Mutlib | www.frontagelab.com |
Frontage Holdings Corporation, a contract research organization, provides laboratory and related services to pharmaceutical, biotechnology, and agrochemical companies. It offers laboratory testing services, such as method development and validation, and sample analysis and central laboratory services; chemistry, manufacturing, and control services, including assistance in drug product development and analysis, and delivery and supply of clinical trial materials; and drug metabolism and pharmacokinetic services. The company also provides early stage clinical/bioequivalence services; absolute bioavailability and human radiolabel studies; and chemistry services, including performing custom synthesis.
Frontage Holdings Corporation Fundamentals Summary
| 1521 fundamental statistics | |
|---|---|
| Market cap | HK$2.73b |
| Earnings (TTM) | HK$84.42m |
| Revenue (TTM) | HK$2.03b |
32.3x
P/E Ratio1.3x
P/S RatioIs 1521 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1521 income statement (TTM) | |
|---|---|
| Revenue | US$259.86m |
| Cost of Revenue | US$181.46m |
| Gross Profit | US$78.39m |
| Other Expenses | US$67.59m |
| Earnings | US$10.81m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0053 |
| Gross Margin | 30.17% |
| Net Profit Margin | 4.16% |
| Debt/Equity Ratio | 23.6% |
How did 1521 perform over the long term?
See historical performance and comparison